Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — 41st Annual J.P. Morgan Healthcare Conference (January 2023)
34 slides from Halozyme Therapeutics's conference presentation, Jan 10, 2023
Slide 1: 41st Annual J.P. Morgan Healthcare Conference
41st Annual J.P. Morgan Healthcare Conference Dr. Helen Torley, President and CEO January 10, 2023 Halozyme Confidential and Proprietary 1
Slide 2: Forward Looking Statements
Forward Looking Statements I n addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company’s expected future financial performance (including the Company's financial outlook for
Slide 3: What We Do: License Drug Delivery Platforms to Partners, and Commercialize Specialty Products
What We Do: License Drug Delivery Platforms to Partners, and Commercialize Specialty Products Drug Delivery Platform Technologies Commercial Portfolio ENHANZE® Auto-Injectors Specialty Products Commercially-Validated Commercialized & Sub-Cutaneous Delivery development stage devices for broad • 5 app
Slide 4: 2023 Select Financial Guidance Highlights
2023 Select Financial Guidance Highlights 2022 2023 Total Revenue $655M - $685M $815M - $845M >20% YoY growth Royalty Revenue $350M - $360M $445M - $455M >20% YoY growth >30% YoY growth EBITDA $310M - $335M $415M - $440M Excludes impact of amortization costs in 2023 related to the Antares acquisitio
Slide 5: Halozyme Investment Highlights
Halozyme Investment Highlights Profitable, high-growth New Potential Royalty New Opportunity 2023: biopharma company with Revenue Opportunity ENHANZE® plus large diversified revenue streams volume auto-injectors • 2 Potential ENHANZE® SC (LVAI) Approvals in 2023 • 2 Additional Potential ENHANZE® SC
Slide 6: Halozyme: Delivering Strong & Durable Growth
Halozyme: Delivering Strong & Durable Growth 01 Differentiated Growth Platforms 02 >$1B ENHANZE® Opportunity 03 Specialty Product Opportunity 04 Durable Revenue and Financial Strength Halozyme Confidential and Proprietary 6
Slide 7: The World Needs More Subcutaneous Large and Small Molecule Drug Delivery
The World Needs More Subcutaneous Large and Small Molecule Drug Delivery Potential benefits for Potential benefits for Healthcare System Patient and Caregivers (providers, nurses, pharmacists, payers) ▪ Potential to decrease healthcare costs: ▪ Decreased treatment burden – Less use of more costly ho
Slide 8: ENHANZE: Patented, De-risked, Commercial Platform Technology Enabling Rapid, Large Volume Subcutaneous Delivery
ENHANZE®: Patented, De-risked, Commercial Platform Technology Enabling Rapid, Large Volume Subcutaneous Delivery of IV Drugs ENHANZE® Uniquely enables rapid SC delivery • 5-15mL over 2-5 minutes • 300-600mL at 5 mL/min Decreased injection site swelling and induration Aids absorption leading to incre
Slide 9: Established Drug Delivery Leadership: Globally-Approved Partner Products, Robust and Diverse Pipeline
Established Drug Delivery Leadership: 5 Globally-Approved Partner Products, Robust and Diverse Pipeline 2 Partner Products in Regulatory Review 5 100+ >600,000 4 Partner Products in/soon to start Phase 3 Approved Countries Patients have received Products ENHANZE®–enabled SC products 8 Partner Produc
Slide 10: Multiple Target Opportunities Open for ENHANZE
Multiple Target Opportunities Open for ENHANZE® Targets Taken Available IV High Volume Therapeutic Area Exclusively Targets* Oncology 9 23 CNS 1 10 Hematologic 1 11 Autoimmune Diseases 4 8 In Cardiovascular/Metabolic 0 6 Infectious Disease 5 5 TOTAL 20 63 Sources: Ev aluate Ltd and Citeline Pharmapr
Slide 11: Differentiated Proprietary and Partner Small Volume Auto-Injectors
Halozyme Differentiated Proprietary and Partner Small Volume Auto-Injectors (SVAI),Commercially Available and Widely Licensable QuickShot™ and VIBEX™ VAI™ Pen Injector BigShot™ Auto Injectors Auto Injectors Auto Injectors Systems 1 mL and 2.25 mL 1 mL 2.25 mL 1.5 mL and 3.0 mL SC or IM SC or IM SC o
Slide 12: NEW in 2023: ENHANZE Plus Auto-Injector Facilitates >5mL to 10mL Auto-Injector
NEW in 2023: ENHANZE® Plus Auto-Injector Facilitates >5mL to 10mL Auto-Injector Halozyme Auto-Injector Large Volume + Technology and Know How >5mL Auto-Injector • Creates space for fluid Customizable technology to 2023: Complete dispersion meet partner needs clinical feasibility testing • Reduces ba
Slide 13: Halozyme: Delivering Strong & Durable Growth
Halozyme: Delivering Strong & Durable Growth 01 Differentiated Growth Platforms 02 >$1B ENHANZE® Opportunity 03 Specialty Product Opportunity 04 Durable Revenue and Financial Strength Halozyme Confidential and Proprietary 13
Slide 14: ENHANZE: Durable Revenue Potential and Strong Future Growth Opportunities
ENHANZE®: Durable Revenue Potential and Strong Future Growth Opportunities Waves 1 & 2 Wave 3 Wave 4 Wave 5 5 Globally-Approved 10 Product Products 4 Product Candidates Candidates Launch Potential Launch Potential Launch Potential 2023-2025 2025-2027 2027+ Efgartigimod SC* New nominations from 8 in/
Slide 15: ENHANZE: A Royalty Growth Story
ENHANZE®: A Royalty Growth Story Projected Royalty Revenue Potential $1B Drivers Drivers Current Portfolio + Wave 5 ENHANZE® Products Co-formulation patents Wav es 1, 2, 3 and 4 submitted 2022-2027 ENHANZE® Products NEW rHuPH20 with Granted and extended room temp. $350-360M submitted co- formulation
Slide 16: Total Royalties: Projecting Record Royalty Revenue in 2023
WAV E 01 02 03 04 Total Royalties: Projecting Record Royalty Revenue in 2023 Projecting >20% growth in 2023 Annual Total Royalty Revenue* ($M) $445-$455 $350-$360 $203.9 $88.6 $69.9 2019 2020 2021 2022E 2023E *Includes auto-injector royalties Halozyme Confidential and Proprietary 16
Slide 17: Wave 2: Launch Growth Drivers – DARZALEX SC/FASPRO
WAV E 01 02 03 04 Wave 2: Launch Growth Drivers DARZALEX SC/FASPRO® Share and Revenue Growth Continues DARZALEX FASPRO® Share of Total Total DARZALEX® Sales IV+SC ($B) 1 US DARZALEX® Sales2 16 $14.5 $13.8 14 $13.0 $12.0 83% 85% 80% 12 $10.9 76% 72% 10 $9.5 66% $8.0 8 $6.0 6 $4.2 4 2 0 Q2 2021 Q3 202
Slide 18: Wave 2: Launch Growth Drivers – Phesgo
WAV E 01 02 03 04 Wave 2: Launch Growth Drivers Phesgo® Share and Revenue Growth Continues Total Perjeta® Sales ($B) 1 Phesgo®2 4.7 $4.6 4.6 $4.6 $4.5 4.5 $4.4 4.4 $4.3 4.3 4.2 4.1 4.0 2021 2022E 2023E 2024E 2025E 1 Analysts’ consensus from Evaluate Ltd October 2022 2 Roche's Third Quarter 2022 Resu
Slide 19: Wave 3: Four Potential Launches 2023-2025
WAV E 01 02 03 04 Wave 3: Four Potential Launches 2023-2025 Products Disease Areas Milestones Potential Launch 1 Completed SC with ENHANZE ® BLA IV APPROVED gMyasthenia Gravis submission in September 2022 2023 Efgartigimod for (gMG) Other Indications Additional SC with ENHANZE® data gMyasthenia Grav
Slide 20: Wave 3: Developing SC Versions of Diverse, Blockbuster Products
WAV E 01 02 03 04 Wave 3: Developing SC Versions of Diverse, Blockbuster Products Parent Products Projected at >$30B in 20281 Efgartigimod Atezolizumab Nivolumab Ocrelizumab First-in-class anti-FcRn Leading anti-PDL1 Currently approved in Number 1 Multiple Sclerosis 10+ cancer types treatment US and
Slide 21: Efgartigimod SC: Potential to Transform Treatment Approach for Patients with Autoimmune Diseases
WAV E 01 02 03 04 Efgartigimod SC: Potential to Transform Treatment Approach for Patients with Autoimmune Diseases Efgartigimod sales $4.7B in 2028, Extensiv e SC Dev elopment ENHANZE® with significant ex-US sales1 and Large Opportunity Potential Impact WW Total BILLIONS Opportunity $5.0 SC IV SC st
Slide 22: Atezolizumab SC: Potential to Reduce Treatment Burden
WAV E 01 02 03 04 Atezolizumab SC: Potential to Reduce Treatment Burden, Help Alleviate Infusion Clinic Capacity Constraints Total Atezolizumab sales ~$7B in SC Opportunity ENHANZE® 2028, with significant ex-US sales1 Potential Impact BILLIONS TECENTRIQ Monotherapy TECENTRIQ IV +/- Oral Therapy Comb
Slide 23: Nivolumab SC: Potential to Reduce Treatment Burden
WAV E 01 02 03 04 Nivolumab SC: Potential to Reduce Treatment Burden, Help Alleviate Infusion Clinic Capacity Constraints Total Niv olumab sales ~$13.4B in 2028, with significant ENHANZE® ex-US sales1 Potential Impact BILLIONS $16.0 • Phase 3 SC Opdiv o monotherapy studies ongoing $14.0 • Renal Cell
Slide 24: Ocrelizumab SC: Meaningful Reduction in Administration and Observation Schedule
WAV E 01 02 03 04 Ocrelizumab SC: Meaningful Reduction in Administration and Observation Schedule Adds to Competitive Profile Ocrelizumab sales ~$8.2B in 2028, ENHANZE® with significant ex-US sales1 Potential Impact BILLIONS ENHANZE® could reduce administration and observ ation schedule to 60 $9.0 m
Slide 25: Wave 4: Multiple Potential Launches
WAV E 01 02 03 04 Wave 4: Multiple Potential Launches Analysts’ Consensus Revenue For All Parent Products in 2028: >$60B1 IMMUNE/ ONCOLOGY HIV AUTOIM M UN E Nivolumab+Relatlimab Teprotumumab-trbw N6LS bnAb (ViiV) (BMS) (Horizon) Cabotegravir (ViiV) IV APPROVED IV APPROVED Oral and IM SC soon to star
Slide 26: Halozyme: Delivering Strong & Durable Growth
Halozyme: Delivering Strong & Durable Growth 01 Differentiated Growth Platforms 02 >$1B ENHANZE® Opportunity 03 Specialty Product Opportunity 04 Durable Revenue and Financial Strength Halozyme Confidential and Proprietary 26
Slide 27: Testosterone Replacement Therapy Portfolio: Targeting >$100M XYOSTED Revenue in 2023
Testosterone Replacement Therapy Portfolio: Targeting to Generate >$100M XYOSTED Revenue in 2023 FOCUS FOCUS OPPORTUNITY ~8.5M TRX prescribed for testosterone replacement therapy in 2022 Once-a-week dosing 2X/daily oral Growing ~5% YOY administration Virtually painless subcutaneous injection using S
Slide 28: Halozyme: Delivering Strong & Durable Growth
Halozyme: Delivering Strong & Durable Growth 01 Differentiated Growth Platforms 02 >$1B ENHANZE® Opportunity 03 Specialty Product Opportunity 04 Durable Revenue and Financial Strength Halozyme Confidential and Proprietary 28
Slide 29: Halozyme Strategic and Capital Allocation Priorities
Halozyme Strategic and Capital Allocation Priorities Invest to Maximize Continue to Return Capital Identify Opportunities Revenue Growth and to Shareholders for External Growth Durability • ENHANZE® Second Plan: December 2021 • Focus on integration • Auto-injector innovation $750M 3-year share buyba
Slide 30: 2023: Projected Acceleration in Royalty Generating Products
2023: Projected Acceleration in Royalty Generating Products 2023 2024 2025 WAVE 2 DARZALEX® SC Royalties Phesgo® Potential Approv al PIPELINE Efgartigimod SC Potential Royalties Potential Approv al Atezolizumab SC Efgartigimod SC CIDP ITP Pemphigus Phase 3 Data Readouts Ocrelizumab SC Multiple Scler
Slide 31: 2023 Financial Guidance Highlights
2023 Financial Guidance Highlights 2022 2023 • >20% YoY growth • Product Sales expected to increase due to full year Antares Total Revenue $655M - $685M $815M - $845M • contribution and increasing ENHANZE API demand Includes one new deal milestones • Total collaboration revenue expected to be relati
Slide 32: Appendix
Appendix Halozyme Confidential and Proprietary 32
Slide 33: ENHANZE Partner Product Development Pipeline
ENHANZE® Partner Product Development Pipeline Wave 3 Pipeline Current Program/Product Indications Phase 1 Phase 2 Phase 3 Filed Wave 3 Efgartigimod (argenx) MG Atezolizumab (Roche) NSCLC Ocrelizumab (Roche) Multiple sclerosis Nivolumab (BMS) RCC Nivolumab (BMS) Melanoma Efgartigimod (argenx) CIDP Ef
Slide 34: ENHANZE Partner Product Development Pipeline
ENHANZE® Partner Product Development Pipeline Wave 4 Pipeline Current Program/Product Indications Phase 1 Phase 2 Phase 3 Filed Wave 4 Amivantamab (Janssen) Solid malignancies Nivolumab+Relatlimab (BMS) Solid tumors Phase 3 to start soon ARGX-117 (argenx) Multifocal motor neuropathy Teprotumumab-trb
Halozyme Therapeutics — 41st Annual J.P. Morgan Healthcare Conference (January 2023) on 6ix